This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (88)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Who Is at Risk?

Richard A. Cooper, MD

Arch Intern Med. 1983;143(4):659-660.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Captopril is a new drug effective both in the treatment of hypertension and in the management of refractory congestive heart failure. Neutropenia was observed early in the clinical testing of captopril,^1-6 causing the Food and Drug Administration to limit its use in the treatment of hypertension in severely affected patients. However, with added experience, it has become apparent that the risk of neutropenia is different among various patient groups. For patients with uncomplicated hypertension, neutropenia is infrequent and represents no greater a risk than exists with other commonly used drugs. In contrast, for patients with renal dysfunction, particularly those who also have a collagen-vascular disease, neutropenia is a risk that must be carefully balanced by potential therapeutic benefits.

These conclusions are based on an analysis of all cases of captopril-associated neutropenia published or reported to the drug's manufacturer as of July 1982, and also on an assessment of more . . . [Full Text PDF of this Article]

Author Affiliations
Hematology-Oncology Section Hospital of the University of Pennsylvania 3400 Spruce St Philadelphia, PA 19104

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?